Syn stocktwits trial#
Regulatory agency recognition builds upon the encouraging clinical data generated to date VCN-01 has been evaluated in 72 patientsĪcross four Phase 1 clinical trials, including patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer,Įnrollment progressed in the Phase 1b/2a clinical trial of SYN-004 (ribaxamase) in allogeneic hematopoietic cell transplant (HCT) Previously been granted ODD by the EMA for the treatment of pancreatic cancer. FDA for the treatment of retinoblastoma VCN-01 has In February of 2022, VCN-01 received Orphan Drug Designation (ODD) from the U.S. Which incorporates a proprietary albumin binding domain in the virus shell with the potential to extend the effectiveness of the therapy. Pipeline updates: The acquisition of VCN Biosciences transformed Syntheticīiologics’ pipeline with the addition of VCN's lead clinical-stage drug candidate, VCN-01, as well as preclinical stage VCN-11, Robust and sustained anti-tumor response by the patient’s immune system. Privately held VCN Biosciences, developer of a novel oncolytic adenovirus (OV) platform designed for intravenous (IV), intravitreal (IVit)Īnd intratumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a VCN acquisition: Synthetic Biologics completed the acquisition of Reported financial results for the year ended December 31, 2021, and provided a corporate update.
(NYSE American: SYN), aĭiversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today
0 kommentar(er)
